Applying Biopharmaceutical Classification System Criteria to Predict the Potential Effect of Cremophor^® RH 40 on Fexofenadine Bioavailability at Higher Doses

References

• Chen C . Some pharmacokinetic aspects of the lipophilic terfenadine and zwitterionic fexofenadine in humans. Drugs. R. D.8(5), 301–314 (2007).
   PubMedGoogle Scholar
• Simons FER . The value of a broad therapeutic index for antihistamine. Adv. Stud. Med.2(24), 872–876 (2002).
   Google Scholar
• Telfast™ prescribing information: sanofi-aventis. (2019). www.medicines.org.au/files/swptelfa.pdf
   Google Scholar
• Cvetkovic M , LeakeB , FrommMF , WilkinsonGR , KimRB. OATP and P-glycoprotein transporters mediate the cellular uptake and excretion of fexofenadine. Drug. Metab. Dispos.27(8), 866–871 (1999).
   PubMed Web of Science ®Google Scholar
• Shimizu M , FuseK , OkudairaKet al. Contribution of OATP (organic anion-transporting polypeptide) family transporters to the hepatic uptake of fexofenadine in humans. Drug. Metab. Dispos.33(10), 1477–1481 (2005).
   PubMed Web of Science ®Google Scholar
• Morrissey KM , WenCC , JohnsSJ , ZhangL , HuangSM , GiacominiKM. The UCSF–FDA TransPortal: a public drug transporter database. Clin. Pharmacol. Ther.92(5), 545–546 (2012).
   PubMed Web of Science ®Google Scholar
• Miura M , UnoT , TateishiT , SuzukiT. Pharmacokinetics of fexofenadine enantiomers in healthy subjects. Chirality19(3), 223–227 (2007).
   PubMed Web of Science ®Google Scholar
• Baggot JD . Bioavailability and bioequivalence of veterinary drug dosage forms, with particular reference to horses: an overview. J. Vet. Pharmacol. Ther.15(2), 160–173 (1992).
   PubMed Web of Science ®Google Scholar
• Zhou H . Pharmacokinetic strategies in deciphering atypical drug absorption profiles. J. Clin. Pharmacol.43(3), 211–227 (2003).
   PubMed Web of Science ®Google Scholar
• Lappin G , ShishikuraY , JochemsenRet al. Pharmacokinetics of fexofenadine: evaluation of a microdose and assessment of absolute oral bioavailability. Eur. J. Pharm. Sci.40(2), 125–131 (2010).
   PubMed Web of Science ®Google Scholar
• Custodio J , WuC-Y , BenetL. Predicting drug disposition, absorption/elimination/transporter interplay and the role of food on drug absorption. Adv. Drug. Deliv. Rev.60(6), 717–733 (2008).
   PubMed Web of Science ®Google Scholar
• Yáñez J , RemsbergC , SayreC , ForrestM , DaviesN. Flip-flop pharmacokinetics – delivering a reversal of disposition: challenges and opportunities during drug development. Ther. Deliv.2(5), 643–672 (2011).
   PubMedGoogle Scholar
• Garrison K , SahinS , BenetL. Few drugs display flip-flop pharmacokinetics and these are primarily associated with classes 3 and 4 of the BDDCS. J. Pharm. Sci.104(9), 3229–3235 (2015).
   PubMed Web of Science ®Google Scholar
• Amidon GL , LennernäsH , ShahVP , CrisonJR. A theoretical basis for a biopharmaceutic drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability. Pharm. Res.12(3), 413–420 (1995).
   PubMed Web of Science ®Google Scholar
• Löbenberg R , AmidonGL. Modern bioavailability bioequivalence and biopharmaceutics classification system. New scientific approaches to international regulatory standards. Eur. J. Pharm. Biopharm.50(1), 3–12 (2000).
   PubMed Web of Science ®Google Scholar
• Martinez MN , AmidonGL. A mechanistic approach to understanding the factors affecting drug absorption: a review of fundamentals. J. Clin. Pharmacol.42(6), 620–643 (2002).
   PubMed Web of Science ®Google Scholar
• Dahan A , MillerJM , AmidonGL. Prediction of solubility and permeability class membership: provisional BCS classification of the world's top oral drugs. AAPS J.11(4), 740–746 (2009).
   PubMed Web of Science ®Google Scholar
• Shekhawat BP , PokharkarBV. Understanding peroral absorption: regulatory aspects and contemporary approaches to tackling solubility and permeability hurdles. Acta. Pharm. Sin. B.7(3), 260–280 (2017).
   PubMed Web of Science ®Google Scholar
• Robbins DK1 , CastlesMA , PackDJ , BhargavaVO , WeirSJ. Dose proportionality and comparison of single and multiple dose pharmacokinetics of fexofenadine (MDL 16455) and its enantiomers in healthy male volunteers. Biopharm. Drug. Dispos.19(7), 455–463 (1998).
   PubMed Web of Science ®Google Scholar
• Maher S , BraydenDJ , CasettariL , IllumL. Application of permeation enhancers in oral delivery of macromolecules: an update. Pharmaceutics.11(1), 41 (2019).
   PubMed Web of Science ®Google Scholar
• Huang J , SiL , JiangL , FanZ , QiuJ , LiG. Effect of pluronic F68 block copolymer on P-glycoprotein transport and CYP3A4 metabolism. Int. J. Pharm.356(1-2), 351–353 (2008).
   PubMedGoogle Scholar
• Wei Z , YuanS , HaoJ , FangX. Mechanism of inhibition of P-glycoprotein mediated efflux by Pluronic P123/F127 block copolymers: relationship between copolymer concentration and inhibitory activity. Eur. J. Pharm. Biopharm.83(2), 266–274 (2013).
   PubMed Web of Science ®Google Scholar
• Wandel C , KimRB , WoodAJJ , SteinCM. “Inactive” excipients such as Cremophor can affect in vivo drug disposition. Clin. Pharmacol. Ther.73(5), 394–396 (2003).
   PubMed Web of Science ®Google Scholar
• Meyer JD , ManningMC , CarpenterJF. Effects of potassium bromide disk formation on the infrared spectra of dried model proteins. J. Pharm. Sci.93(2), 496–506 (2004).
   PubMed Web of Science ®Google Scholar
• International Conference on Harmonisation (ICH) of Technical Requirements for Registration of Pharmaceuticals for Human Use. ICH Harmonised Tripartite Guideline: Guideline for Good Clinical Practice, (1996). (2019). http://apps.who.int/medicinedocs/documents/s22154en/s22154en.pdf
   Google Scholar
• Helmy S , ElBedaiwy H. HPLC determination of fexofenadine in human plasma for therapeutic drug monitoring and pharmacokinetic studies. Biomed. Chromatogr.30(7), 1059–1064 (2016).
   PubMed Web of Science ®Google Scholar
• Higuchi T . Mechanism of sustained-action medication. Theoretical analysis of rate of release of solid drugs dispersed in solid matrices. J. Pharm. Sci.52, 1145–1149 (1963).
   PubMed Web of Science ®Google Scholar
• Bourne DW . Pharmacokinetics. In: Modern Pharmaceutics (4^th Edn).BankerGS, RhodesCT ( Eds). Marcel Dekker Inc, NY, USA (2002).
   Google Scholar
• El-Yazigi A . Disintegration-dissolution analysis of percent dissolved-time data. J. Pharm. Sci.70(5), 535–537 (1981).
   PubMed Web of Science ®Google Scholar
• Costa P , SousaLobo JM. Modeling and comparison of dissolution profiles. Eur. J. Pharm. Sci.13(2), 123–133 (2001).
   PubMed Web of Science ®Google Scholar
• Liu Q , FassihiR. Zero-order delivery of a highly soluble, low dose drug alfuzosin hydrochloride via gastro-retentive system. Int. J. Pharm.348(1-2), 27–34 (2008).
   PubMedGoogle Scholar
• Zhang Y , HuoM , ZhouJet al. DDSolver: an add-in program for modeling and comparison of drug dissolution profiles. AAPS J.12(3), 263–271 (2010).
   PubMed Web of Science ®Google Scholar
• Gibaldi, Perrier . Pharmacokinetics2nd Edn. Marcel Dekker Inc, NY, USA409–417 (1982).
   Google Scholar
• Gabrielsson J , WeinerD. Pharmacokinetic and Pharmacodynamic Data Analysis: Concepts and Applications4th Edn. Swedish Pharmaceutical Press, Stockholm, Sweden (2006).
   Google Scholar
• Westlake WF . Use of confidence interval in analysis of comparative bioavailability trials. J. Pharm. Sci.61(8), 1340–1341 (1972).
   PubMed Web of Science ®Google Scholar
• Hummel J , McKendrickS , BrindleyC , FrenchR. Exploratory assessment of dose proportionality: review of current approaches and proposal for a practical criterion. Pharm. Stat.8(1), 38–49 (2009).
   PubMed Web of Science ®Google Scholar
• U.S. Food and Drug Administration Centre for Drug Evaluation and Research (FDA) . Guidance for Industry: Statistical Approaches to Establishing Bioequivalence, Office of Training and Communications, Division of Communications Management, Drug Information Branch, HFD-210, Rockville MD 20857, January 2001. (2019). www.fda.gov/media/70958/download
   Google Scholar
• Steinijans VW , HauschkeD. Update on the statistical analysis of bioequivalence studies. Int. J. Clin. Pharmacol. Ther. Toxicol.30(Suppl. 1), S45–S50 (1992).
   PubMedGoogle Scholar
• Joyner SP ( Ed.). SAS/STAT Guide for Personal Computers, Version 8.2SAS Institute, NC, USA (2001).
   Google Scholar
• Gough K , HutchisonM , KeeneOet al. Assessment of dose proportionality: report from the statisticians in the pharmaceutical industry/pharmacokinetics UK joint working party. Drug. Info. J.29(3), 1039–1048 (1995).
   Google Scholar
• Smith B , VandenhendeF , DeSanteKet al. Confidence interval criteria for assessment of dose proportionality. Pharm. Res.17(10), 1278–1283 (2000).
   PubMed Web of Science ®Google Scholar
• U.S. Food and Drug Administration Centre for Drug Evaluation and Research (FDA) . Guidance for Industry: Bioavailability and Bioequivalence Studies for Orally Administered Drug Products–General Considerations, Office of Training and Communications, Division of Communications Management, Drug Information Branch, HFD-210, Rockville MD 20857, (2003). www.fda.gov/media/76764/download [2019].
   Google Scholar
• Sheng Y , HeY , HuangX , YangJ , WangK , ZhengQ. Systematic evaluation of dose proportionality studies in clinical pharmacokinetics. Curr. Drug. Metab.11(6), 526–537 (2010).
   PubMed Web of Science ®Google Scholar
• WHO . Multisource (generic) pharmaceutical products: guidelines on registration requirements to establish Interchangeability. WHO Expert Committee on Specifications for Pharmaceutical Products: forty-ninth report. World Health Organization: Geneva; 2015: Annex 7 (WHO Technical Report Series, No. 992), (2015).
   Google Scholar
• Varma MV , KhandavilliS , AshokrajYet al. Biopharmaceutic classification system: a scientific framework for pharmacokinetic optimization in drug research. Curr. Drug. Metab.5(5), 375–388 (2004).
   PubMed Web of Science ®Google Scholar
• Chavda HV , PatelCN , AnandIS. Biopharmaceutics classification system. Sys. Rev. Pharm.1(1), 62–69 (2010).
   Google Scholar
• Yu LX , EllisonCD , ConnerDP , LeskoLJ , HussainAS. Influence of drug release properties of conventional solid dosage forms on the systemic exposure of highly soluble drugs. AAPS Pharm. Sci.3(3), 86–92 (2001).
   Google Scholar
• Sugano K . Calculation of fraction of dose absorbed: comparison between analytical solution based on one compartment steady state concentration approximation and dynamic seven compartment model. Chem. Bio. Informat. J.9, 75–93 (2009).
   Google Scholar
• Yehia S , El-RidiM , TadrosM , El-SherifN. Enhancement of the oral bioavailability of fexofenadine hydrochloride via Cremophor® El-based liquisolid tablets. Adv. Pharm. Bull.5(4), 569–581 (2015).
   PubMedGoogle Scholar
• Matsaridou I , BarmpalexisP , SalisA , NikolakakisL. The influence of surfactant HLB and oil/surfactant ratio on the formation and properties of self-emulsifying pellets and microemulsion reconstitution. AAPS Pharm. Sci. Tech.13(4), 1319–1330 (2012).
   PubMed Web of Science ®Google Scholar
• Jahan ST , KhanSR , MoniruzzamanRahman R , SadatS , JalilR. Enhancement of dissolution profile for oral delivery of Fexofenadine Hydrochloride by solid dispersion (solvent evaporation) technique. Am. J. Sci. Ind. Res.2(1), 112–115 (2011).
   Google Scholar
• Kiss L , WalterFR , BocsikAet al. Kinetic analysis of the toxicity of pharmaceutical excipients Cremophor EL and RH40 on endothelial and epithelial cells. J. Pharm. Sci.102(4), 1173–1181 (2013).
   PubMed Web of Science ®Google Scholar
• Landín M , GonzálezMP , SoutoC , ConcheiroA , Gómez-AmozaJL , Martínez-PachecoR. Comparison of two varieties of microcrystalline cellulose as filler-binders II. Hydrochlorothiazide tablets. Drug. Dev. Ind. Pharm.19(10), 1211–1220 (1993).
   Web of Science ®Google Scholar
• Desai D , ZiaH , QuadirA. Evaluation of selected micronized poloxamers as tablet lubricants. Drug. Deliv.14, 413–426 (2007).
   PubMed Web of Science ®Google Scholar
• Kwon HJ , HeoE-J , KimY-Het al. Development and evaluation of poorly water-soluble celecoxib as solid dispersions containing nonionic surfactants using fluidized-bed granulation. Pharmaceutics.11(136), 1–13 (2019).
   Google Scholar
• Santos JV , Batistade Carvalho LAE , PinaMET. The Influence of the compression force on zidovudine release from matrix tablets. AAPS Pharm. Sci. Tech.11(3), 1442–1448 (2010).
   PubMed Web of Science ®Google Scholar
• Delalonde M , RuizT. Dissolution of pharmaceutical tablets: the influence of penetration and drainage of interstitial fluids. Chem. Eng. Process.47(3), 370–376 (2008).
   Web of Science ®Google Scholar
• El-Bagory I , BarakatN , IbrahimMA , El-EnaziF. Formulation and in vitro evaluation of theophylline matrix tablets prepared by direct compression: Effect of polymer blends. Saudi. Pharm. J.20(3), 229–238 (2012).
   PubMed Web of Science ®Google Scholar
• Gundogdu E , GonzalezA , BermejoSanz M , KarasuluE. Assessment of fexofenadine hydrochloride permeability and dissolution with an anionic surfactant using Caco-2 cells. Pharmazie.66(10), 747–753 (2011).
   PubMed Web of Science ®Google Scholar
• The official pharmacopeial method for dissolution of fexofenadine HCL tablets . The United States Pharmacopeial Convention USPNF, (2009). (2020). www.uspnf.com/sites/default/files/usp_pdf/EN/USPNF/fexofenadineHydrochlorideTablet.pdf
   Google Scholar
• Unvala HM , SchwartzJB , SchnaareRL. The effect of the wet granulation process on drug dissolution. Drug. Dev. Ind. Pharm.14(10), 1327–1349 (1988).
   Web of Science ®Google Scholar
• Saigal N , BabootaS , AhujaA , AliJ. Microcrystalline cellulose as a versatile excipient in drug research. J. Young. Pharm.1(1), 6–12 (2009).
   Google Scholar
• Tayrouz Y , DingR , BurhenneJet al. Pharmacokinetic and pharmaceutic interaction between digoxin and Cremophor RH40. Clin. Pharmacol. Ther.73(5), 397–405 (2003).
   PubMed Web of Science ®Google Scholar
• Gibaldi M , FeldmanS. Mechanisms of surfactant effects on drug absorption. J. Pharm. Sci.59(5), 579–589 (1970).
   PubMed Web of Science ®Google Scholar
• Gelderblom H , VerweijJ , NooterK , SparreboomA. Cremophor EL: the drawbacks and advantages of vehicle selection for drug formulation. Eur. J. Cancer37(13), 1590–1598 (2001).
   PubMed Web of Science ®Google Scholar
• Steffansen B , NielsenCU , BrodinB , ErikssonAH , AndersenR , FrokjaerS. Intestinal solute carriers: An overview of trends and strategies for improving oral drug absorption. Eur. J. Pharm. Sci.21(1), 3–16 (2004).
   PubMed Web of Science ®Google Scholar
• Giacomini KM , HuangSM , Tweedie DJet al. Membrane transporters in drug development. Nat. Rev. Drug. Discov.9(3), 215–236 (2010).
   PubMed Web of Science ®Google Scholar
• Rege BD , KaoJP , PolliJE. Effects of nonionic surfactants on membrane transporters in caco-2 cell monolayers. Eur. J. Pharm. Sci.16(4-5), 237–246 (2002).
   PubMed Web of Science ®Google Scholar
• Benoit JP , LanprechtL. Use of p-glycoprotein inhibitor surfactant at the surface of a colloidal carrier. Patent W02004071498; (2004).
   Google Scholar
• Anderberg EK , NyströmC , ArturssonP. Epithelial transport of drugs in cell culture. VII: Effects of pharmaceutical surfactant excipients and bile acids on transepithelial permeability in monolayers of human intestinal epithelial (Caco-2) cells. J. Pharm. Sci.81(9), 879–887 (1992).
   PubMed Web of Science ®Google Scholar
• Sancho-Chust V , Fabra-CamposS , Gómez-MeseguerV , BengocheaM , Martín-VillodreA. Experimental studies on the influence of surfactants on intestinal absorption of drugs. Cefadroxil as model drug and sodium lauryl sulfate as model surfactant: studies in rat colon. Arzneimittelforschung.45(5), 595–601 (1995).
   PubMed Web of Science ®Google Scholar
• Hugger ED , AudusKL , BorchardtRT. Effects of poly(ethylene glycol) on efflux transporter activity in Caco-2 cell monolayers. J. Pharm. Sci.91(9), 1980–1990 (2002).
   PubMed Web of Science ®Google Scholar
• Bernstein DI , SchoenwetterWF , NathanRA , StormsW , AhlbrandtR , MasonJ. Efficacy and safety of fexofenadine hydrochloride for treatment of seasonal allergic rhinitis. Ann. Allergy. Asthma Immunol.79(5), 443–448 (1997).
   PubMed Web of Science ®Google Scholar
• Tillement JP . The advantages for an H1 antihistamine of a low volume of distribution. Allergy55(Suppl. 60), 17–21 (2000).
   PubMedGoogle Scholar
• Mahar Doan KM , WringSA , ShampineLJet al. Steady-state brain concentrations of antihistamines in rats: interplay of membrane permeability, P-glycoprotein efflux and plasma protein binding. Pharmacology72(2), 92–98 (2004).
   PubMed Web of Science ®Google Scholar
• Molimard M , DiquetB , BenedettiMS. Comparison of pharmacokinetics and metabolism of desloratadine, fexofenadine, levocetirizine and mizolastine in humans. Fundam. Clin. Pharmacol.18(4), 399–411 (2004).
   PubMed Web of Science ®Google Scholar
• Golightly LK , GreosLS. Second-generation antihistamines: actions and efficacy in the management of allergic disorders. Drugs65(3), 341–384 (2005).
   PubMed Web of Science ®Google Scholar
• Garrison KL , SahinS , BenetLZ. Garrison KL1, Sahin S1, 2, Benet LZ1. Few drugs display flip-flop pharmacokinetics and these are primarily associated with classes 3 and of the BDDCS. J. Pharm. Sci.104(9), 3229–3235 (2015).
   PubMed Web of Science ®Google Scholar
• Toutain PL , Bousquet-MelouA. Volumes of distribution. J. Vet. Pharmacol. Ther.27(6), 441–453 (2004).
   PubMed Web of Science ®Google Scholar
• Savjani KT , GajjarAK , SavjaniJK. Drug solubility: importance and enhancement techniques. ISRN Pharm.2012, 195727 (2012).
   PubMedGoogle Scholar
• Jain S , PatelN , LinS. Solubility and dissolution enhancement strategies: current understanding and recent trends. Drug. Dev. Ind. Pharm.41(6), 875–87 (2015).
   PubMed Web of Science ®Google Scholar
• Oh DM , SinkoPJ , AmidonGL. In: Predicting oral drug absorption in humans: a macroscopic mass balance approach for passive and carrier-mediated compounds. Advanced methods of Pharmacokinetic and Pharmacodynamic Systems Analysis.D'ArgenioDZ ( Ed.). Springer, NY, USA, 3–11 (1991).
   Google Scholar